Published in J Neurochem on November 01, 2000
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology (2005) 2.33
Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull (2005) 1.02
Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology (Berl) (2008) 0.90
U-69593, a kappa opioid receptor agonist, decreases cocaine-induced behavioral sensitization in female rats. Behav Neurosci (2008) 0.87
Cocaine-induced mu opioid receptor occupancy within the striatum is mediated by dopamine D2 receptors. Brain Res (2009) 0.87
Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats. Psychopharmacology (Berl) (2007) 0.79
Effects of withdrawal from chronic escalating-dose binge cocaine on conditioned place preference to cocaine and striatal preproenkephalin mRNA in C57BL/6J mice. Neuropharmacology (2012) 0.77
Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem (2000) 1.49
Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol (2000) 1.46
Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther (1985) 1.29
Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol (1999) 1.27
Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther (1997) 1.26
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 1.20
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol (1986) 1.14
Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol (1986) 1.13
Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci (2001) 1.13
Quantitative near-infrared spectroscopy of cervical dysplasia in vivo. Hum Reprod (1999) 1.12
Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther (2001) 1.11
Characterization of DorC from Rhodobacter capsulatus, a c-type cytochrome involved in electron transfer to dimethyl sulfoxide reductase. J Biol Chem (1999) 1.08
Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol (1998) 1.07
Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci (1999) 1.05
Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem (2000) 1.04
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther (2000) 1.02
Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther (1986) 1.01
Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience (2001) 0.99
Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J Pharmacol Exp Ther (2001) 0.99
Arc mRNA induction in striatal efferent neurons associated with response learning. Eur J Neurosci (2007) 0.98
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol (1985) 0.97
The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem (2000) 0.97
Effect of methamphetamine on neurotensin concentrations in rat brain regions. J Pharmacol Exp Ther (1987) 0.97
Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res (1994) 0.96
Computer simulation of magnetic resonance spectra employing homotopy. J Magn Reson (1998) 0.96
Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther (1997) 0.96
Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res (1998) 0.96
Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem (1999) 0.96
Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens. Eur J Pharmacol (1989) 0.95
Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Res (1996) 0.95
Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J Pharmacol Exp Ther (1997) 0.94
Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology (1987) 0.94
A purple acid phosphatase from sweet potato contains an antiferromagnetically coupled binuclear Fe-Mn center. J Biol Chem (2001) 0.93
Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology (1987) 0.92
Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol (1997) 0.92
Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects. J Pharmacol Exp Ther (1994) 0.92
Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1988) 0.91
Stimulation of non-neuronal cell proliferation in vitro by mitogenic factors present in highly purified sympathetic neurons. Brain Res (1978) 0.91
Effects of cocaine on extrapyramidal and limbic dynorphin systems. J Pharmacol Exp Ther (1990) 0.90
MDMA: historical perspectives. Ann N Y Acad Sci (1990) 0.90
Elevation of substance P-like immunoreactivity in rat central nervous system by protease inhibitors. J Neurochem (1980) 0.88
A purified ferredoxin from Giardia duodenalis. Eur J Biochem (1994) 0.88
Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience (2005) 0.88
Mutational analysis of the dimethylsulfoxide respiratory (dor) operon of Rhodobacter capsulatus. Microbiology (1999) 0.88
Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. J Pharmacol Exp Ther (1996) 0.87
Methamphetamine-induced depression of monoamine synthesis in the rat: development of tolerance. J Neurochem (1985) 0.87
A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur J Pharmacol (1997) 0.87
Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain. Brain Res (1989) 0.87
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br J Cancer (2003) 0.86
Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J Pharmacol Exp Ther (1994) 0.86
Neuroendocrine actions and regulation of hypothalamic neuropeptide Y during lactation. Peptides (2007) 0.86
Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. Eur J Pharmacol (2000) 0.86
Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity. Neuroscience (1987) 0.86
Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J Pharmacol Exp Ther (1992) 0.86
Neurochemical basis of neurotoxicity. Neurotoxicology (1990) 0.86
Mechanisms for tolerance to methamphetamine effects. Neuropharmacology (1996) 0.85
Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Res Mol Brain Res (1999) 0.84
Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model. J Neurochem (2001) 0.84
m-THPC-mediated photodynamic therapy (PDT) does not induce resistance to chemotherapy, radiotherapy or PDT on human breast cancer cells in vitro. Photochem Photobiol (1998) 0.83
Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. Eur J Pharmacol (1989) 0.83
Methcathinone: an initial study of its effects on monoaminergic systems. J Pharmacol Exp Ther (1996) 0.83
Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur J Pharmacol (1988) 0.83
A comparison of two factors affecting the proliferation of non-neuronal (glial) cells in vitro. Brain Res (1980) 0.83
Expression of the core exon-junction complex factor eukaryotic initiation factor 4A3 is increased during spatial exploration and striatally-mediated learning. Neuroscience (2012) 0.83
Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol (1989) 0.82
Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol (1989) 0.82
Studies on the mechanism of tolerance to methamphetamine. Brain Res (1985) 0.82
Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience (2001) 0.82
Molybdate-dependent expression of dimethylsulfoxide reductase in Rhodobacter capsulatus. FEMS Microbiol Lett (2000) 0.82
Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems. J Pharmacol Exp Ther (1999) 0.81
Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine. Brain Res (1999) 0.81
Characterization of the inhibitor complexes of cobalt carboxypeptidase A by electron paramagnetic resonance spectroscopy. Biochemistry (1989) 0.81
Mechanisms of chemotransmission in the mammalian carotid body. Prog Brain Res (1988) 0.81
Dopamine-mediated gene regulation in the striatum. Adv Pharmacol (1998) 0.80
Detection of hydroxyl and carbon-centred radicals by EPR spectroscopy after ischaemia and reperfusion of the rat kidney. Free Radic Res (1996) 0.80
Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids (1998) 0.80
Cloning and sequence analysis of the dimethylsulfoxide reductase structural gene from Rhodobacter capsulatus. Biochim Biophys Acta (1996) 0.80
Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Brain Res (1992) 0.79
Release of vasoactive intestinal peptide and neuropeptide Y from canine heart. Am J Physiol (1993) 0.79
Characterization of a molybdenum cofactor biosynthetic gene cluster in Rhodobacter capsulatus which is specific for the biogenesis of dimethylsulfoxide reductase. Microbiology (1999) 0.79
Examination of the involvement of protein kinase A in D2 dopamine receptor antagonist-induced immediate early gene expression. J Neurochem (2001) 0.79
Neurotoxicity of amphetamines and their metabolites. NIDA Res Monogr (1997) 0.79
Effects of conantokins on L-3,4-dihydroxyphenylalanine-induced behavior and immediate early gene expression. Eur J Pharmacol (2000) 0.79
Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine. Brain Res (2001) 0.79
Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Res (2000) 0.79
Effects of MK-801 on D1 dopamine receptor-mediated immediate early gene expression in the dopamine-depleted striatum. Brain Res (2000) 0.79
Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment. Brain Res Bull (1987) 0.78
N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems. Brain Res (1991) 0.78
Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems. J Pharmacol Exp Ther (1989) 0.78
A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol (1987) 0.78
Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems. Eur J Pharmacol (1991) 0.78